# Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)

> **NCT07277582** · PHASE2,PHASE3 · RECRUITING · sponsor: **Thryv Therapeutics, Inc.** · enrollment: 64 (estimated)

## Conditions studied

- Long QT Syndrome (LQTS) 2

## Interventions

- **OTHER:** baseline lead-in
- **DRUG:** THRV-1268
- **DRUG:** THRV-1268

## Key facts

- **NCT ID:** NCT07277582
- **Lead sponsor:** Thryv Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07277582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07277582, "Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07277582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*